NO20070912L - Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander - Google Patents

Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander

Info

Publication number
NO20070912L
NO20070912L NO20070912A NO20070912A NO20070912L NO 20070912 L NO20070912 L NO 20070912L NO 20070912 A NO20070912 A NO 20070912A NO 20070912 A NO20070912 A NO 20070912A NO 20070912 L NO20070912 L NO 20070912L
Authority
NO
Norway
Prior art keywords
treatment
conditions
nervous system
system disorders
procedure
Prior art date
Application number
NO20070912A
Other languages
English (en)
Norwegian (no)
Inventor
Darlene Coleman Deecher
Arthur Jay Cohn
Magid A Abou-Gharbia
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070912L publication Critical patent/NO20070912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20070912A 2004-07-22 2007-02-16 Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander NO20070912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020304P 2004-07-22 2004-07-22
PCT/US2005/025974 WO2006012474A1 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (1)

Publication Number Publication Date
NO20070912L true NO20070912L (no) 2007-04-20

Family

ID=35149631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070912A NO20070912L (no) 2004-07-22 2007-02-16 Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander

Country Status (14)

Country Link
US (2) US20060020015A1 (OSRAM)
EP (1) EP1773320A1 (OSRAM)
JP (1) JP2008507550A (OSRAM)
KR (1) KR20070034126A (OSRAM)
CN (1) CN101410106A (OSRAM)
AU (1) AU2005266994A1 (OSRAM)
BR (1) BRPI0512186A (OSRAM)
CA (1) CA2574310A1 (OSRAM)
IL (1) IL180731A0 (OSRAM)
MX (1) MX2007000853A (OSRAM)
NO (1) NO20070912L (OSRAM)
RU (1) RU2007102292A (OSRAM)
WO (1) WO2006012474A1 (OSRAM)
ZA (1) ZA200700578B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
BRPI0512182A (pt) * 2004-07-22 2008-02-19 Wyeth Corp método para o tratamento de condições e desordens do sistema nervoso
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions
US8000005B2 (en) * 2006-03-31 2011-08-16 Prysm, Inc. Multilayered fluorescent screens for scanning beam display systems
EP1904059A2 (en) * 2005-07-21 2008-04-02 Wyeth a Corporation of the State of Delaware Method for treating nervous system disorders and conditions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
GR72713B (OSRAM) * 1976-09-15 1983-12-01 American Cyanamid Co
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3378208D1 (en) * 1982-12-21 1988-11-17 Ciba Geigy Ag Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
RU2004120285A (ru) * 2001-12-05 2005-04-10 Уайт (Us) Новый кристаллический полиморф гидрохлорида венлафаксина и способы его получения
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions

Also Published As

Publication number Publication date
BRPI0512186A (pt) 2008-02-19
WO2006012474A1 (en) 2006-02-02
KR20070034126A (ko) 2007-03-27
EP1773320A1 (en) 2007-04-18
AU2005266994A1 (en) 2006-02-02
JP2008507550A (ja) 2008-03-13
MX2007000853A (es) 2007-03-26
CN101410106A (zh) 2009-04-15
CA2574310A1 (en) 2006-02-02
US20060020015A1 (en) 2006-01-26
IL180731A0 (en) 2007-07-04
US20120010260A1 (en) 2012-01-12
ZA200700578B (en) 2010-06-30
RU2007102292A (ru) 2008-08-27

Similar Documents

Publication Publication Date Title
NO20070912L (no) Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander
NO20070915L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
SE0202241D0 (sv) Novel Compounds
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
TW200407305A (en) Novel compounds
TW200510301A (en) Novel compounds
NO20072887L (no) Forbindelser og sammensetninger som protein kinase inhibitorer
MY151032A (en) Treatment of tnf? related disorders
EP1793671A4 (en) USE OF MEMANTINE (NAMENDA) FOR THE TREATMENT OF AUTISM, FORCED BEHAVIOR AND IMPULSIVITY
CY1107274T1 (el) Παραγωγα αλφα-αμινοαμιδιου χρησιμα σαν παραγοντες κατα της ημικρανιας
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
NO20074332L (no) Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
WO2023077127A3 (en) Psychoplastogenic n-substituted indoles
JO3352B1 (ar) صيغ دايكلوفيناك وطرق استخدامه
WO2006058338A3 (en) 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
NO20065768L (no) Karbonsamid-opioidforbindelser
ZA200802238B (en) 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
WO2006012476A3 (en) Method for treating nervous system disorders and conditions
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders